Onconova Therapeutics

Onconova Therapeutics CEO Ramesh Kumar

The biotech: Onconova Therapeutics
Round: $50 million
Based: Newtown, PA
CEO: Ramesh Kumar
Investors: Undisclosed

The scoop: Onconova unveiled the big round back in August in a filing with the SEC. And a month later it put out the word that Baxter International ($BAX) had stepped in with a $50 million upfront to license European rights for its late-stage cancer drug rigosertib. The biotech has a full slate of mid- and late-stage studies under way on the experimental drug, a multikinase inhibitor targeting mitotic and PI-3 kinase pathways. Investigators are pursuing a study for an IV formulation of rigosertib for patients with myelodysplastic syndromes who have failed other drugs or relapsed. And a Phase II/III is enrolling pancreatic cancer patients, one of the toughest cancer populations any developer can tackle. An early-stage study for acute myelogenous leukemia is also being prepped.

For more:
Baxter and Onconova ink $500M-plus licensing pact for PhIII cancer drug
Onconova hauls in $50M to fuel late-stage leukemia program

Onconova Therapeutics

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.